Oral NNI-351 Awarded Orphan Drug Status by FDA
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NeuroNascent’s NNI-351 for the treatment of fragile X syndrome. NNI-351, given orally, is able to penetrate the brain, where it has been shown to boost the proliferation and growth of immature progenitor cells into mature…